Page 5 - Immunology_11_2021
P. 5

SPARK THE                                                                           1.5 mg/0.5 mL



        MOTIVATION FOR CHANGE



        IN YOUR TYPE 2 DIABETES PATIENTS



        Powerful dose from the start without the need to titrate¹

















































       Powerful HbA1c              Proven CV benefit             Simple once-weekly            Better adherence
          reduction  1,*           in patients with or               dosing in a              shown in real-world
                                   without established         ready-to-use pen with           studies vs. other
                                         CVD  2,3,†               hidden needle   1,4            GLP-1 RAs  5,6‡






        *Trulicity 1.5mg demonstrated statistically superior HbA1C in patients with type 2 diabetes in 8 phase III clinical trials vs metformin, sitagliptin, exenatide BID, insulin glargine, and/or placebo. Trulicity 1.5mg demonstrated
        noninferior HbA1c reduction vs liraglutide 1.8mg, as well as noninferiority vs insulin glargine in patients with type 2 diabetes and CKD 1  PP-DG-ZA-0359
        † Trulicity 1.5mg significantly reduced the risk of MACE-3 (composite of non-fatal MI, non-fatal stroke, or CV death) vs. placebo by 12% on top of standard of care. CV benefit was consistent across subgroups of patients with
        and without estabalished CVD 2,3
        ‡ In real-world studies, ~40% more patients with T2DM were adherent to once-weekly Trulicity relative to once-weekly semaglutide, Moreover, persistence with Trulicity was the highest among GLP1 RAs including twice daily
        exenatide, once-weekly exenatide, liraglutide and lixisenatide
        References: 1. Trulicity (dulaglutide once weekly) Trulicity Professional Information, Eli Lilly and Company, Johannesburg, South Africa - 2020. 2. Gerstein HC, et al. Lancet. 2019 ;394:121-130 3. Gerstein HC, et al. Diabetes
        Obes Metab. 2018;20:42-49 4. Trulicity 1.5mg instructions for use 5. Mody R, et al. Diabetes Obes Metab.2021;23:106-115. 6. Divino V, et al. Diabetes Ther. 2019;10:1067-1088

             Trulicity ® . Reg No. 51/21.13/0344 Dulaglutide 1,5 mg/ 0,5ml solution for injection. For more product information, please email us at: za_medinfo@lilly.com
        S4
        For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority Eli Lilly (S.A.) (Pty) Ltd. Reg. No. 1957/000371/07 1st Floor, Golden Oak
        House, Ballyoaks Office Park, 35 Ballyclare Drive, Bryanston, JohannesburgTel: +27 (11) 510 9300
        © 2020 Eli Lilly and Company. All Rights Reserved.
   1   2   3   4   5   6   7   8   9   10